BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - FRA:BRM - US1101221083 - Common Stock
39.955 EUR
+1.03 (+2.66%)
BRM gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.33%, BRM is in line with its industry, outperforming 51.92% of the companies in the same industry.
BRM's Return On Equity of 28.96% is fine compared to the rest of the industry. BRM outperforms 78.85% of its industry peers.
BRM has a better Return On Invested Capital (15.09%) than 76.92% of its industry peers.
BRM had an Average Return On Invested Capital over the past 3 years of 10.96%. This is below the industry average of 15.23%.
The last Return On Invested Capital (15.09%) for BRM is above the 3 year average (10.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROIC | 15.09% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
BRM has a Profit Margin (10.58%) which is in line with its industry peers.
With a decent Operating Margin value of 30.27%, BRM is doing good in the industry, outperforming 78.85% of the companies in the same industry.
In the last couple of years the Operating Margin of BRM has declined.
With a decent Gross Margin value of 73.92%, BRM is doing good in the industry, outperforming 65.38% of the companies in the same industry.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
The number of shares outstanding for BRM has been reduced compared to 1 year ago.
BRM has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BRM is higher compared to a year ago.
2.2 Solvency
BRM has an Altman-Z score of 2.03. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.03, BRM is not doing good in the industry: 63.46% of the companies in the same industry are doing better.
BRM has a debt to FCF ratio of 3.37. This is a good value and a sign of high solvency as BRM would need 3.37 years to pay back of all of its debts.
BRM has a Debt to FCF ratio of 3.37. This is comparable to the rest of the industry: BRM outperforms 57.69% of its industry peers.
A Debt/Equity ratio of 2.56 is on the high side and indicates that BRM has dependencies on debt financing.
With a Debt to Equity ratio value of 2.56, BRM is not doing good in the industry: 80.77% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Altman-Z | 2.03 |
ROIC/WACC1.92
WACC7.87%
2.3 Liquidity
A Current Ratio of 1.21 indicates that BRM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.21, BRM perfoms like the industry average, outperforming 40.38% of the companies in the same industry.
A Quick Ratio of 1.11 indicates that BRM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.11, BRM is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 391.24%, which is quite impressive.
The earnings per share for BRM have been decreasing by -24.57% on average. This is quite bad
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 2.57%.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
3.2 Future
BRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.11% yearly.
Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -4.99% on average per year.
EPS Next Y467.96%
EPS Next 2Y131.17%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue Next Year-1.07%
Revenue Next 2Y-4.7%
Revenue Next 3Y-3.54%
Revenue Next 5Y-4.99%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.85, the valuation of BRM can be described as very cheap.
Based on the Price/Earnings ratio, BRM is valued cheaper than 94.23% of the companies in the same industry.
BRM is valuated cheaply when we compare the Price/Earnings ratio to 26.10, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 7.57, which indicates a rather cheap valuation of BRM.
BRM's Price/Forward Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 92.31% of the companies in the same industry.
BRM is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.52, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.85 | ||
| Fwd PE | 7.57 |
4.2 Price Multiples
92.31% of the companies in the same industry are more expensive than BRM, based on the Enterprise Value to EBITDA ratio.
96.15% of the companies in the same industry are more expensive than BRM, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.44 | ||
| EV/EBITDA | 6.01 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM's earnings are expected to grow with 73.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y131.17%
EPS Next 3Y73.61%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 5.66%, which is a nice return.
Compared to an average industry Dividend Yield of 2.98, BRM pays a better dividend. On top of this BRM pays more dividend than 92.31% of the companies listed in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.66% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
98.12% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP98.12%
EPS Next 2Y131.17%
EPS Next 3Y73.61%
FRA:BRM (10/31/2025, 7:00:00 PM)
39.955
+1.03 (+2.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap81.33B
Revenue(TTM)47.70B
Net Income(TTM)5.05B
Analysts67.27
Price Target44.24 (10.72%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.66% |
Yearly Dividend2.08
Dividend Growth(5Y)11.67%
DP98.12%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.2%
Min EPS beat(2)19.36%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)21.86%
Min EPS beat(4)13.54%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)17.22%
EPS beat(12)11
Avg EPS beat(12)11.73%
EPS beat(16)15
Avg EPS beat(16)9.9%
Revenue beat(2)2
Avg Revenue beat(2)5.24%
Min Revenue beat(2)3.68%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)5.13%
Min Revenue beat(4)3.68%
Max Revenue beat(4)6.79%
Revenue beat(8)7
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)1.72%
Revenue beat(16)10
Avg Revenue beat(16)1.44%
PT rev (1m)-0.49%
PT rev (3m)-6.94%
EPS NQ rev (1m)-8.17%
EPS NQ rev (3m)-8.34%
EPS NY rev (1m)-1.68%
EPS NY rev (3m)-2.69%
Revenue NQ rev (1m)0.43%
Revenue NQ rev (3m)1.53%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)2.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.85 | ||
| Fwd PE | 7.57 | ||
| P/S | 1.97 | ||
| P/FCF | 6.44 | ||
| P/OCF | 5.91 | ||
| P/B | 5.39 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.01 |
EPS(TTM)5.83
EY14.59%
EPS(NY)5.27
Fwd EY13.2%
FCF(TTM)6.2
FCFY15.52%
OCF(TTM)6.76
OCFY16.93%
SpS20.29
BVpS7.42
TBVpS-10.94
PEG (NY)0.01
PEG (5Y)N/A
Graham Number31.19
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROCE | 21.51% | ||
| ROIC | 15.09% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 95.64% | ||
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% | ||
| FCFM | 30.56% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Debt/EBITDA | 2.14 | ||
| Cap/Depr | 20.37% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | 288.73% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 2.03 |
F-Score7
WACC7.87%
ROIC/WACC1.92
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
EPS Next Y467.96%
EPS Next 2Y131.17%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
Revenue Next Year-1.07%
Revenue Next 2Y-4.7%
Revenue Next 3Y-3.54%
Revenue Next 5Y-4.99%
EBIT growth 1Y30.41%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.71%
FCF growth 1Y35.99%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y34.19%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 5 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 4 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 467.96% in the next year.